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health and disease, yet important gaps remain in basic knowledge and its translation to clinical
care. AMP-activated protein kinase (AMPK) functions either to conserve ATP or to promote
alternative methods of ATP generation. Since the discovery of AMPK more than three decades ago
and demonstration of its expression in the heart, interest has grown exponentially in this major fuel
gauge as a modulator of the cellular response to ischemia. Such pathway may potentially explain
the strong association between metabolic syndrome and ischemic heart disease. Still missing from
our most recent cardiology textbooks, this article aims to summarize our understanding so far of
the role of AMPK in coordinating the cellular response to ischemic stress and reperfusion injury in
the heart. We aim to provide a focused update on the pharmacological agents activating AMPK for
treatment of diabetes that show potential cardioprotective effects. Our hope is to stimulate future
researchers to the potential beneﬁts of harnessing the AMPK signaling pathway, or better one of its
novel downstream targets for the treatment of myocardial ischemia.
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Figure 1 Schematic representation of the different forms of
AMPK. Increases in AMP relative to ATP, sensed as a low
energy state, allows AMPKK to phosphorylate Thr172 and
activate AMPK at the N-terminal of the a subunit (i). This occurs
in situations of stress and may be simulated by different
pharmacological agents. The active form of AMPK (ii) is now
available to lead the myriad of changes in cellular metabolism.
Abundance of ATP, as in high energy states, allows ATP to bind
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Heart disease remains the leading cause of death worldwide in
spite of the dramatic improvements in the management of
acute myocardial infarction. While the underlying pathophy-
siology of the atherosclerotic process is not signiﬁcantly
different in diabetic subjects, the prothrombotic and procoa-
gulant state with which diabetes is associated is thought to
contribute to the higher incidence of and worse prognosis after
myocardial infarction1. Following reperfusion with percuta-
neous coronary intervention or thrombolytics, infarct size
propagation seemed inevitable2. That was when attention
has turned to cellular adaptive mechanisms in the hope to
improve mortality and morbidity of myocardial infarction.
AMPK has stood out over the past decade as a master
conductor orchestrating the intracellular metabolic process,
both at the cellular level and in experimental animal
models3–6. It functions as a sensor during low energy states,
such as ischemia, to change substrate utilization and thereby
increase ATP synthesis. AMPK also seemed to put the cell in
‘survival mode’ conserving energy that would otherwise be
consumed in non-urgent anabolic processes7–9. Since then
AMPK has emerged as a very promising target for cytopro-
tective therapy10–15. Our perception of the AMPK pathway
continues to evolve as we better understand the intricate
relationships between AMPK and its upstream and down-
stream kinases. The aim of the current review is to discuss the
beneﬁts and potential harms of AMPK activation during
myocardial infarction, especially in the diabetic population
and shed light on the pros and cons of currently available
AMPK activators.
to AMPK causing a conformational change that renders it
vulnerable to degrading phosphatases (iii). Phosphorylation of
AMPK by Akt at Ser485/491 in response to insulin causes another
conformational change that prevents AMPKKs from binding and
activating AMPK (iv).2. Structure of AMPK
AMPK is a widely distributed, highly conserved heterotrimeric
enzyme composed of a catalytic a (63 kDa) subunit and the
non-catalytic b and g subunits5 (Fig. 1). There are two genes
encoding isoforms of both the a and b subunits (a1, a2, b1 and
b2). The a2 isoform is the subunit of AMPK found predomi-
nantly within cardiac muscles16. AMPK is activated by
AMPK kinase (AMPKK) by phosphorylation of threonine-
172 at the N-terminal end of the a subunits17,18. The close
proximity of AMPK to cellular glycogen stores allows it to
rapidly affect changes in glycogen metabolism in response to
changes in the metabolic demands19. Binding sites for AMP
are found on the regulatory g subunits which also bind
ATP16,20. Of clinical signiﬁcance is the observation that
mutations in the g2 subunit, the dominant isoform in the
heart (gene symbol PRKAG2), are associated with abnormal
glycogen accumulation in cardiomyoctes manifesting as
Wolff–Parkinson–White syndrome and familial hypertrophic
cardiomyopathy21. The binding of AMP and ATP to AMPK
occurs in a mutually exclusive manner17. An increased AMP
to ATP ratio leads to a conformational change in AMPK that
makes it a poorer substrate for degrading protein phospha-
tases and a better substrate for AMPKK5,17. Because of its dual
effect, small rises in AMP levels can induce a dramatic rise in the
activity of AMPK22. Adenylate kinase maintains its reaction
(2ADP2ATPþAMP) close to equilibrium, therefore the
AMP:ATP ratio varies as the square of the ADP:ATP ratio,
and this makes the AMP:ATP ratio a very sensitive indicator ofcellular energy charge23. Similar positive allosterism is also
observed with an increased creatinine:phosphocreatine ratio20.
Activation of AMPK leads to phosphorylation of many target
proteins important for ATP synthesis and utilization as well as
the inhibition of ATP-consuming pathways such as fatty acid
synthesis11,24. Once the energy stores are replenished, the binding
of ATP maintains the activity of AMPK low25.3. Upstream regulators of AMPK
There are at least three different upstream AMPK kinases
(AMPKKs), the most widely expressed being LKB1 (with two
accessory subunits, STRADa/b and MO25a/b) which is
critical for the gluconeogenic ﬂux and consequently glucose
homeostasis26,27. AMPK phosphorylation during myocardial
ischemia however seems to be related, in addition, to
AMPKKs other than LKB1 as observed by Altarejos et al.28
AMPK activity was noted to be increased in mild ischemia
before the classic shift in the AMP:ATP and creatine:pho-
sphocreatinine ratios17,29. One other activator of AMPK is
Ca2þ-calmodulin–protein kinase kinase b (CaMKK-b) which
phosphorylates and activates AMPK in response to increased
Ca2þ ﬂuxes providing a mechanism for cells to anticipate the
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described by Anderson et al.32,33 is the autophosphorylation of
CaMKK-b after sustained exposure to Ca2þ. This might
contribute to sustained myocardial stunning and ischemia
reperfusion injury (RI) following myocardial infarction. The
third AMPK phosphorylating kinase is transforming growth
factor-b-activated kinase 1 (TAK1)34. TAK1, a member of the
mitogen-activated protein kinase kinase kinase (MAPKKK)
family, is a key mediator of proinﬂammatory and stress
signals29,35. TAK1 was initially found to activate the AMPK
analogue in yeast, Snf1 before being linked to mammalian
AMPK34. A large body of promising research is being invested
in each upstream kinase to determine which one is predomi-
nantly expressed in the heart and is the ﬁrst domino in the
cardiomyocyte response to ischemic stress cascade and post-
MI remodeling. Detailed discussion of each of these kinases is
beyond the scope of this article and is readily available for the
avid reader. Most likely the cellular response to ischemia
initiating AMPK activation is interplay of all three kinases
and others. Adiponectin, a plasma protein with cardioprotec-
tive, antidiabetic and anti-inﬂammatory properties also exerts
its action through AMPK activation36,37. Of note is that
adiponectin levels were found to correlate inversely with
insulin resistance, obesity and coronary artery disease possibly
explaining why patients with diabetes and ischemic heart
disease have worse prognoses38. Furthermore sestrins, a family
of conserved proteins that accumulate in cells exposed to stress,
and lack kinase activity have been recently shown to potentiate
the activation of AMPK independent of AMP:ATP39. Little is
known about which phosphatase regulates AMPK. Both type
2A and type 2C protein phosphatases (PP2A and PP2C,
respectively) are good candidates since they can dephosphor-
ylate and deactivate AMPK in vitro40.4. Downstream targets of AMPK in the heart
Activation of AMPK in the heart leads to a myriad of changes
affecting glucose and lipid metabolism, protein synthesis and
gene expression3,41. AMPK activation induces the transloca-
tion of glucose transporter 4 (GLUT4) to the plasma mem-
brane by a mechanism distinct to that of insulin and not
clearly understood42,43. It augments the binding of transcrip-
tion factor myocyte enhancing factor-2 (MEF-2) to promoters
in the GLUT4 gene increasing its expression44. Under hypoxic
conditions in the heart, AMPK activates phosphofructoki-
nase-2 (PFK-2), the product of which is fructose 2, 6-bipho-
sphate (Fru2, 6-P2)45,46. This molecule allosterically regulates
phosphofructokinase-1 and in the liver fructose 1, 6-bipho-
sphatase, favoring glycolysis over gluconeogenesis. This
phenomenon, recognized as the Pasteur Effect is responsible
for increased ATP production through anaerobic glycolysis
during ischemia45. AMPK also inhibits both isoforms of
Acetyl-CoA carboxylase (ACC1 and ACC2) through phos-
phorylation47. This eventually leads to decreased inhibition of
carnitine palmitoyltransferase I (CPTI) in the mitochondria
and increased b-oxidation of fatty acids4,6. Increased fatty acid
oxidation, like increased glycolysis will lead to valuable
increases in ATP production in stress conditions. One impor-
tant concept in energy production is the Randle cycle where
the utilization of one nutrient inhibits the use of the other
directly and without hormonal mediation48. The glucose-fattyacid cycle is thus a biochemical mechanism that controls fuel
selection and adapts substrate supply and demand in normal
tissues in coordination with hormones controlling substrate
concentrations in the circulation49.
In addition AMPK phosphorylates and inactivates
HMG-CoA reductase, hormone-sensitive lipase, as well as
transcription factors hepatic nuclear factor 4a (HNF4a) and
sterol regulatory element binding proteins 1c and -2 (SREBP-1c
and -2)50. This reduces energy consumption at the cellular level
and in the long term atherogenic dyslipidemia. AMPK further
conserves ATP expenditure by inhibiting liver glycogen synthase
and creatine kinase51.
With regards to protein metabolism, activation of AMPK
phosphorylates and activates endothelial nitric oxide synthase
(eNOS) in cardiac endothelium causing NO-mediated vasodi-
latation and improved perfusion4,42. NO activation in platelets
leads to a decrease in thrombin-induced aggregation, thereby,
limiting the pro-coagulant effects of platelet activation52.
AMPK activation regulates protein synthesis through inhibi-
tion of elongation factor 2 (eEF2) and indirectly through
inhibition of mammalian target of rapamycin (mTOR)53. Of
clinical signiﬁcance is the use of mTOR inhibitors in drug-
eluting stents to inhibit protein synthesis and restenosis
following reestablishing blood ﬂow. Another promising tran-
scription factor and downstream target of AMPK recently
linked to improved cardiac oxidative stress is Forkhead box
protein (FoxO)54. Mice with deletion of FoxO1 and FoxO3 were
found to have increased scar formation, induction of stress-
responsive signaling, and apoptotic cell death in response to
ischemia55. Peroxisome proliferator-activated receptor gamma
coactivator 1 alpha (PGC-1a) is a multi-functional transcrip-
tional coactivator involved in the regulation of cardiac mito-
chondrial biogenesis and oxidative phosphorylation56. It is
activated by AMPK and sirtuin 1 (SIRT1) through phosphor-
ylation and deacetylation, respectively57. Phosphorylated AMPK
also indirectly activates PGC-1a through SIRT1 by promoting
an intracellular increase in NADþ levels, the rate-limiting
substrate for the deacetylase activity of SIRT158. Once turned
on, PGC-1a boosts mitochondrial activity to adapt to the
increased energy requirements.5. AMPK regulates autophagy
AMPK is also involved in triggering autophagy in the heart
during ischemia and reperfusion59. Autophagy is a lysosomal
pathway involved in the turnover of cell’s own macromole-
cules and organelles9. This has been identiﬁed as an adaptive
cell response allowing the cell to survive otherwise lethal
challenges by removing damaged organelles and misfolded
proteins. The principle is to conserve energy that would
otherwise be used in non-essential pathways. In addition free
fatty acids and amino acids produced by the degradation of
these organelles are then recycled to maintain mitochondrial
ATP production and ribosomal protein synthesis60. Recent
studies have shown that AMPK is involved in triggering
autophagy in the heart in response to ischemia59. Activated
AMPK inhibits mammalian target of rapamycin complex 1
(mTORC1/mTOR) activity via a pathway involving tuberous
sclerosis complex 1 and 2 (TSC1/2) thus stimulating autop-
hagy53. Recent studies unveiled that ULK1 is a mediator for
AMPK modulating autophagy9,61,62.
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Utilizing the AMPK pathway seems to have a beneﬁcial effect
during myocardial ischemia11,12,14,31,63,64. There is a fairly
stereotypical sequence of physiologic changes that develop
during an episode of spontaneous transmural ischemia3,20.
Under physiological conditions, energy necessary to maintain
myocardial contraction/relaxation cycle is derived from mito-
chondrial oxidation of long chain fatty acids (60–70%) and
carbohydrates (20–30%)3,65,66. Coronary occlusion results in an
immediate fall in coronary venous oxygen saturation, with a
reduction in ATP production64. This causes a decline in regional
contraction within several beats, reaching dyskinesis within
1 min67. As regional contraction ceases, there is a reduction in
global LV contractility (dP/dt), a progressive rise in LV end-
diastolic pressure and a fall in systolic pressure. AMPK there-
fore is activated in response to the decreased concentration of
ATP in order to boost energy production and sustain the
cardiomyocyte during this time of metabolic stress3,4. The
magnitude of systemic hemodynamic changes varies with the
severity of ischemia and the amount of the left ventricle
subjected to ischemia. ST-segment changes on EKG develop
within 2 min as efﬂux of potassium into the extracellular space
reaches a critical level68. Irreversible injury begins after 20 min
following a total occlusion but is delayed for up to 5 h following
a partial occlusion69. The timing of administering a drug that
activates AMPK is thus crucial, ideally as soon as possible
following presentation.7. AMPK in reperfusion injury
Following restoration of blood ﬂow before irreversible injury,
several types of RI have been observed in experimental
animals that exacerbate myocardial infarction70. These consist
of the following: (1) lethal reperfusion injury – reperfusion-
induced death of cells that were still viable at the time of
restoration of coronary blood ﬂow; (2) vascular reperfusion
injury – progressive damage to the microvasculature so that
there is an expanding area of no reﬂow and loss of coronary
vasodilatory reserve; (3) stunned myocardium – salvaged myo-
cytes display a prolonged period of contractile dysfunction
following restoration of blood ﬂow because of abnormalities
of intracellular metabolism leading to reduced energy produc-
tion; and (4) reperfusion arrhythmias – bursts of ventricular
tachycardia and, on occasion, ventricular ﬁbrillation – that
occur within seconds of reperfusion. The exact mechanism of RI
remains incompletely understood, but is thought to include
(i) cytosolic and mitochondrial Ca2þ-overload, (ii) release of
reactive oxygen species (ROS), (iii) changes in pH and intrami-
tochondrial Hþ71, (iv) shift in substrate use, and (v) recruitment
of inﬂammatory cells attacking viable myocytes. In concert,
these derangements result in the formation of mitochondrial
permeability transition pore (mPTP) upon reperfusion (Fig. 2).
It spans both the inner and outer membranes and, when open,
causes collapse of the transmembrane voltage gradient C and
uncoupling of the mitochondria. Pore formation would prevent
mitochondrial ATP production at reperfusion, a time when the
ischemic but still salvageable myocytes would need it the most72.
We now know that AMPK is stimulated by all of these changes.
AMPK is activated by CaMKK-b in response to (i)73 and is
redox-sensitive to (ii) and (iii)74. Decreased ATP:AMP (iv) andTAK1 in response to inﬂammatory cytokines (v) also activate
AMPK. In addition, AMPK seems to inhibit the opening of
mPTP and reduce infarct size in animal models75. Transgenic
mice heart expressing a kinase dead form of AMPK demon-
strated impaired recovery of left ventricular contractility and
increased apoptosis on reperfusion11. A group of protective
kinases, referred to as reperfusion injury salvage kinases (RISK),
were found to somehow prevent transition pore formation at
reperfusion. This comprises phosphatidylinositol 3-kinase
(PI3K), Protein kinase B (Akt) and p42/p44 extra-cellular
signal-regulated kinases (Erk 1/2). Even though AMPK has
not been identiﬁed as a member of the RISKs, many of the
agents that activate AMPK were also found to activate the
RISK pathway including metformin, pioglitazone, statins and
adenosine76. While autophagy in myocardial ischemia is cardi-
oprotective as a means to conserve energy, continued autophagy
upon reperfusion seems to be harmful with a shift more towards
programmed cell death59. This however was shown to be due to
beclin 1, independent of AMPK77.
Needless to say that the graveness of reperfusion injury is
proportional to the duration of ischemia. The effectiveness of
agents directed against reperfusion injury rapidly declines the
later they are administered after reperfusion; eventually, no
beneﬁcial effect is detectable in animal models after 45 to
60 min of reperfusion has elapsed75.8. Pharmacological agents
A very interesting combination of drugs has emerged that utilize
the AMPK pathway. There are two groups of antihyperglyce-
mics: metformin and glitazones (TZDs), an adenosine analogue
tested in bypass surgery, a drug formerly used in sepsis, a
thienopyridone and statins, which are the only drugs currently
approved for acute coronary syndrome. Cannabinoids, present
in marijuana have also been found, in a small study, to stimulate
AMPK in the heart and hypothalamus of rats78.
8.1. Metformin
First used in 1957, it is the most commonly used drug for
treatment of type 2 diabetes. The activation of AMPK by
metformin is mediated indirectly through increased AMP:ATP
ratio. This is hypothesized to occur through weak inhibition of
complex I of the respiratory chain and a relative fall in cellular
ATP concentration79. This inhibits AMPK dephosphorylation
thereby potentiating its phosphorylation by the upstream kinase
LKB180. Adenine nucleotide-independent mechanisms have also
been postulated but poorly understood81,82. The cardioprotective
actions of metformin through AMPK are not solely limited to its
ability to reduce myocardial infarct size, as demonstrated by
Calvert et al.83 with the acute administration before ischemia or at
reperfusion. The dose used for AMPK activation of 125 mg/kg79
was much less than the maximum therapeutic dose of 2550 mg84.
A very recent study has shown the cardioprotective beneﬁts of
metformin extend beyond acute coronary syndrome (ACS) to
cardiac transplantation. Murine hearts treated with metformin
perioperatively were found to have signiﬁcantly better graft
beating scores and less luminal narrowing, an effect that lasted
more than 50 day post surgery79. This is believed to be mainly due
to decreased RI, apoptosis and cardiac allograft vasculopathy
secondary to AMPK activation. Chronic metformin therapy in
Figure 2 Illustration of the role of AMPK during reperfusion. AMPK activation in early reperfusion increases the uptake of glucose and
long chain fatty acids (LCFA) into the cell. This coincides with increased anaerobic glycolysis and fatty acid oxidation for ATP
production. In the absence of insulin, fatty acids are preferred over glucose for oxidation resulting in the uncoupling of end products of
glycolysis. Both AMPK and RISK function to prevent the opening of mPTP and loss of the electrochemical gradient within the
mitochondria. Autophagy is turned on initially by AMPK inhibition of mTOR and later by beclin 1.
Amr Moussa, Ji Li372diabetic patients is also known to improve lipoprotein proﬁles,
reduce oxidative stress, and improve vascular stability85. Dogs
with tachycardia-induced heart failure were found to have
improved left ventricular function with chronic AMPK activa-
tion with metformin or AICAR86. The metformin dose used
there was 100 mg/kg/day, similar to the therapeutic dose for
diabetes. Advantages of metformin use are its good bioavail-
ability and relatively safe proﬁle. The dose for optimal AMPK
activation is yet to be determined. An interesting question arises
when considering metformin in ameliorating ischemia/reperfu-
sion injury in the setting of ACS. Would diabetic patients
already on chronic metformin therapy (assuming AMPK
activation) beneﬁt from a ‘booster’ dose of metformin as much
as naive patients?8.2. Glitazones (TZDs)
Rosiglitazone and pioglitazone are insulin sensitizers. Pioglitazone
is the only drug remaining in this class that may be prescribed
without restriction. TZDs bind to the nuclear membrane receptors
PPARg (peroxisome proliferator-activated receptors gamma) and
affect DNA expression. Like metformin, TZDs have been found
to increase the AMP:ATP ratio leading to AMPK activation87.
PPARg agonists further activate AMPK through increased
expression of adiponectin88,89. Most experiments have been done
using rosiglitazone as it is the most selective and potent PPARg
agonist in its class90. Rosiglitazone treatment also has beenshown to reduce myocardial apoptosis and infarction size post
RI by restoring the balance between the pro-apoptotic and anti-
apoptotic mitogen-activated protein kinases (MAPKs), increas-
ing phosphatidylinositol-3-kinase (PI3K)-Akt phosphorylation,
and inhibiting p42/44 MAPK91.
The association between TZDs and heart failure is well
recognized as a class effect3. Fluid retention is mediated through
increased sodium reabsorption of the renal PPARg-dependent
pathway in the collecting tubules. In 2007, a meta-analysis by
Nissen et al.92 suggested that use of rosiglitazone in type 2 diabetes
was associated with a signiﬁcant increase in the risk of myocardial
infarction and with an increase in the risk of death from
cardiovascular causes that had borderline signiﬁcance. Although
the method and statistical analysis used in this study have been
criticized, subsequent meta-analyses showed similar concerns93. In
spite of these concerns, one can argue that acute rosiglitazone
administration may prove beneﬁcial in ACS through AMPK
activation regardless of the implicating long-term increased
mortality3,64. Unpublished results from our lab suggest that the
beneﬁt of acute rosiglitazone therapy during myocardial ischemia
is even more pronounced in diabetic mice.8.3. Activated protein C (APC)
APC is a vitamin K-dependent plasma serine protease that
down-regulates clotting and inﬂammatory pathways94.
Because of such properties, APC was approved in septic shock
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signiﬁcant mortality beneﬁt95. In the interim it was found that
APC exerts cardioprotective effects by decreasing apoptosis in
cardiomyocytes and inhibiting expression of inﬂammatory
mediators after myocardial ischemia through AMPK. The
activation of cardiac AMPK by APC was mediated through
the APC receptors: endothelial protein C receptor (EPCR)
and protease activated receptor-1 (PAR-1), and was depen-
dent on CaMKK-b. Moreover, APC decreased inﬂammatory
signaling pathways JNK and NF-kB, and down-regulated the
expression of inﬂammatory cytokines in ischemic hearts.
These cardioprotective effects of APC were abrogated in
AMPKa2 knockout mice31.
8.4. 5-Aminoimidazole-4-carboxamide-1-b-D-ribofuranoside
(AICAR)
AICAR is a drug that is metabolized inside cells into ZMP
(5-aminoimidazole-4-carboxamide-riboside), an analogue of
AMP96. ZMP activates AMPK by direct and allosteric activa-
tion although less effective than AMP17. Balschi et al.97 demon-
strated the AICAR-dependant phosphorylation of AMPK in
isolated mouse heart. Interestingly AICAR made it to phase III
trials, as early as 1994 in (Coronary Artery Bypass Graft)
CABG surgery, long before our current understanding of the
AMPK pathway. This was simply because of the rationale that
increased levels of adenosine potentiates vasodilatation, pre-
conditioning and inhibits inﬂammation98. RED-CABG in 2009,
the last phase III trial involving AICAR, was terminated early
when an interim analysis showed low probability of success.
Limitations to its use include the requirement for intravenous
infusion and variable potency. It also causes bradycardia and
can lead to hypoglycemia when administered intravenously. One
interesting conﬂict is that AICAR has been shown to induce
protein kinase B (Akt), a potent activator of mTORC1, in an
AMPK-independent manner99. Activation of mTORC1 inhibits
autophagy which has been shown to play a role in ameliorating
cardiac ischemic injury.
8.5. A-769662
A cell-permeable small organic compound was identiﬁed as an
effective AMPK activator by screening a chemical library of
over 70,000 compounds followed by lead optimization100. First
found to have beneﬁcial effects on metabolism in db/db mice, A-
769662 was shown to activate AMPK both allosterically and by
inhibiting dephosphorylation of AMPK on Thr172, analogous to
the effects of AMP101. Similarly macrophage migration inhibi-
tory factor (MIF), a pleiotropic cytokine that is released by
ischemic cardiomyocytes was found to exert cardioprotective
effects by activating AMPK10,12. While developing small mole-
cule antagonists of the MIF receptor for immunomodulatory
applications102, the compound MIF20 was uncovered that
signiﬁcantly augmented AMPK phosphorylation in the presence
of MIF (unpublished data). The clinical beneﬁt of those two
compounds however remains largely investigational.
8.6. Statins
HMG-CoA reductase inhibitors have been shown to have
cardiovascular beneﬁts in patients with and without diabetesbeyond their lipid-lowering effects. Actually the pleiotropic
beneﬁts of statins extend to patients without cardiovascular
disease and with normal cholesterol levels103,104. Statins
activate AMPK in the myocardium and endothelial cells by
mechanisms that are not fully understood. Up-regulation of
eNOS by atorvastatin in endothelial cells of mice without
altering AMP:ATP ratio suggests another indirect mechanism
of AMPK activation105. Rossoni et al.106 have shown that
acute simvastatin-mediated relaxation of healthy endothelial
cells of rats was mediated via AMPK and eNOS phosphoryla-
tion. This effect was totally blunted after adding the AMPK
inhibitor, Compound C106.9. AMPK and diabetes
Type 2 diabetes mellitus is a fasting hyperglycemic state of
insulin resistance leading to impaired peripheral glucose utiliza-
tion. A key contributing factor to these abnormalities is the
failure of insulin to suppress gluconeogenesis and hepatic glucose
production. AMPK activity is thought to be impaired in diabetes
as AMPK stimulation in animal models has been shown to
improve glycemia. This was also established using AMPK
activators other than the antidiabetic drugs: metformin and
glitazones107,108. Increasing glucose uptake into the cells and
suppressing endogenous glucose production and lipolysis suggest
AMPK activators as a possible new class of antidiabetic agents.10. Insulin/AMPK interaction
The use of insulin for ACS seemed logical in 1963 by Sodi-
Pallares, with the intention of facilitating potassium ﬂux in the
ischemic myocardium, the so-called polarizing therapy. Glu-
cose and potassium were later added to counteract the effects
of large dose insulin to become known as GIK therapy109.
With the identiﬁcation of the insulin signaling pathway,
insulin was found to have comprehensive anti-inﬂammatory,
antioxidant and antiapoptotic properties through PI3K and
Akt (RISK pathway) independent of AMPK110. Insulin also
suppressed the high blood fatty acid levels commonly
observed in patients with ACS. Insulin-mediated activation
of PI3K-Akt led to activation of endothelial nitric oxide
synthase (eNOS) which inhibited mPTP opening in cardio-
myocyte mitochondria. Yet the promising non-metabolic
effects of insulin failed to translate to signiﬁcant mortality
beneﬁt in a trial comprising 20,000 patients with myocardial
infarction (MI)111. One possible explanation is the dynamic
interaction between insulin and AMPK during ischemia
then reperfusion in the heart. Insulin activates Akt which
directly phosphorylates AMPKa1/a2 on Ser485/491 preventing
AMPKK from phosphorylating AMPKa at its primary
activation site, Thr172.112 This is believed to be beneﬁcial as
decreased AMPK-mediated oxidation of fatty acids relieved
the inhibition of glucose oxidation mainly at the level of
pyruvate dehydrogenase. This rechanneled the end products of
glycolysis into aerobic respiration with subsequent decrease in
the detrimental protons and lactate accumulation. However
this cardioprotective effect demonstrated in isolated hearts
was abolished in the presence of palmitate, simulating the high
free circulating fatty acid levels present during reperfusion113;
an effect that was observed at an insulin concentration of
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palmitate seems to also activate PP2A which dephosphorylates
and inactivates AMPK114. This appears to be in response to
negative feedback by ceramide, a second messenger in the
sphingomyelin signaling pathway. Added to that, heparin that
is conventionally used in ACS, stimulates lipoprotein lipase
increasing further FFA levels and favoring their oxidation.
More studies are needed with different levels of insulin to
better understand the relationship between anabolic insulin
and catabolic AMPK.11. Non-pharmacological AMPK activators
11.1. Caloric restriction
One independent factor increasing AMPK activity is caloric
restriction (CR)115. CR being deﬁned as moderate restriction
(20–40%) of caloric intake compared to ad libitum feeding.
CR has shown promising results in increasing longevity and
reducing the risk factors for cardiovascular disease, diabetes
and cancer116. The exact mechanism of AMPK activation
remains elusive, but the general belief is that CR simulates an
energy-deﬁcient state that is sensed by AMPK as an increase in
the AMP:ATP ratio. Resveratrol, a small polyphenol present in
red grapes, was found to have CR-like metabolic effects
primarily through activation of AMPK117. While utilizing CR
as an inducer of AMPK seems impractical in the setting of acute
myocardial infarction, it is nonetheless a weak one. On a clinical
note, current medical practices entail that most patients
admitted for ACS and planned intervention be in a fasting state
to reduce the risk of aspiration. Further research in CR is
needed to be able to answer when to resume feeds in those
patients and how aggressive we should be controlling glucose
levels in the diabetic subgroup.11.2. Preconditioning and human in vivo model for reperfusion
injury
Charles Murry, a fellow then in Duke University laboratory, ﬁrst
demonstrated the principle of preconditioning (PC) in canine
hearts in 1986. He reported that subjecting the heart to four
cycles of 5-min coronary occlusion/5-min reperfusion would
make the heart very resistant to infarction from a subsequent
lethal ischemic insult119. This seems to be the strongest endo-
genous protective mechanism of the heart. Later PC was divided
into early and late phases, the latter mediated by upregulation of
cardioprotective genes by mechanisms that are still unclear. This
involved the upregulation of inducible nitric oxide synthase
(iNOS), cyclooxygenase-2 (COX2), aldose reductase, 12-Lipox-
ygenase (12-LO) and Mn-superoxide dismutase (Mn-SOD)
leading to enhanced production of NO and PGI2/PGE2 and
removal of oxygen free radicals. One established link is that PC
activates AMPK and upregulates GLUT4 expression in a PKC-
dependent manner120. Others include activation of the RISK
pathway and eventual prevention of mPTP formation. The
clinical applicability of ischemic PC remains limited because of
the obligate need to initiate it before the onset of ischemia which
is seldom possible to predict. However, several strategies using
AMPK activators have been developed that can be applied
before or at the time of reperfusion which mimic ischemic PC.Worth mentioning is the in vivo model of skeletal muscle
preconditioning in humans by Rongen et al.121 from the Nether-
lands. The value of such experiment is that it was the ﬁrst one to
demonstrate preconditioning in humans with fairly reproducible
results. There, ischemia was induced in non-dominant hands by
inﬂating a blood pressure cuff to 200 mmHg followed by
intermittent hand gripping till exhaustion for 10 min followed
by reperfusion. Annexin A5 scintigraphy was used as a marker for
apoptosis. Ischemia–reperfusion injury was then quantiﬁed as the
percentage difference in uptake between experimental and control
hands. Preconditioning was simulated by 10 min of forearm
ischemia and a 10-min period of reperfusion without simultaneous
exercise. Pharmacological preconditioning was done with intra-
arterial adenosine infusion with similar results. Using the same
model in subjects with metabolic syndrome, Rongen et al.122 have
demonstrated improved reperfusion injury in a crossover study of
4 mg bid of AMPK inducer rosiglitazone vs. placebo for 8 weeks.
Numerous papers have been published worldwide showing
promising results regarding utilizing AMPK phosphorylation
in ameliorating ischemia/reperfusion injury on various animal
models10,14,31,64. Only a handful of these have translated to
human research. This in part is due to variations in the
protocols used and reproducibility of the published results.
Some even argue that using animal models is misleading with
the conviction that human myocardium is biochemically more
tolerant to ischemia than animal models. If 20 min of total
occlusion is how long it takes for irreversible myocardial
injury to occur in humans, how much time of acute occlusion
should be simulated in disease-free coronaries with no collat-
erals of mice, rabbits or pigs corrected for their relative
metabolisms? This has lead to the Consortium for preclinicAl
assESsment of cARdioprotective therapies (CAESAR), an
initiative from the NHLBI aimed at the preclinical research118.
The plan of which is to perform systematic preclinical testing
of cardioprotective therapies using standardized protocols
performed by blinded investigators and analyzed by a single
statistical core as done for randomized, multicenter clinical
trials. Pharmacological agents showing consistent results and
statistical power will be promoted to clinical trials.12. Conclusions
The actions of activated AMPK previously described have
generated many questions regarding its potential role in cardio-
vascular disease. AMPK activation during myocardial ischemia
might indeed protect the heart against injury. Additional tremen-
dous applications can include adjuvant therapy to cardiac bypass
surgery, protecting donor hearts before transplant and treatment
of acute ischemic strokes. We now know that activated AMPK
effectively preconditions the heart, improves glucose uptake,
glycoysis and fatty acid oxidation to provide ATP. It also
stimulates autophagy and inhibits cholesterol and glycogen
synthesis to conserve energy during ischemic stress. Other beneﬁts
to AMPK activation during ischemia extend beyond cardio-
myocytes to improve endothelial metabolism, function and
angiogenesis. How much of this response is beneﬁcial and how
much is harmful is not clear. How is the cellular response to
physiological stress different from infarction? To what degree can
we extrapolate the cellular responses in physiological stress
situations as exercise and caloric restriction to pathological
situations as myocardial infarction without making it harmful?
AMPK in myocardial infarction and diabetes: the yin/yang effect 375Since AMPK is rapidly inactivated during reperfusion, sustained
iatrogenic AMPK activation may prove detrimental. Continued
‘switched on’ autophagy would eventually lead to cell death.
Favoring fatty acid over glucose oxidation would exaggerate the
uncoupled ATP production from glycolysis leading to increased
proton and lactate production, cardiac inefﬁciency and contractile
dysfunction.
If one may formulate a drug for the treatment of myocar-
dial infarction with our current understanding of cellular
metabolism, it would be a single-use drug that can be given
within the ﬁrst hour of suspected ACS. It would have the same
potency to directly activate AMPK as Compound A-769662,
with a similar safety and bioavailability as metformin. It
would be a drug selective to AMPK unlike AICAR which
seems to inhibit autophagy through other pathways, but has a
similar half-life as to not persist long after reperfusion. It
would be one that does not cross the blood brain barrier as to
not affect hypothalamic AMP-activated protein kinase. And
ﬁnally it would be a drug that allows fatty acid and glucose
oxidation to go hand in hand like perhaps an AMPK activator
and just the right amount of insulin.
Ultimately, manufacturing such a drug for clinical use must
involve our pharmaceutical friends which, understandably are
not excited about this as clinicians are. With the survival rate
for U.S. patients hospitalized with MI being approximately
95% using conventional therapy, pharmaceutical companies
are less interested in investing into a new single-use drug that
must be administered in a timely fashion prior to reperfusion.
The market for chronic treatments to survivors of MI is much
broader and much more lucrative. Furthermore, enthusiasm
for development of such a drug with so many downstream
effects would be dampened by the required expense of the
clinical trials that would be necessary to obtain approval.
Hopefully with the amount of research being invested in
cardiac cell metabolism and the CAESAR initiative the
pharmaceutical companies will soon pick up the scent.
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